These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 8932352)

  • 1. Initial prognostic factors in small-cell lung cancer patients predicting quality of life during chemotherapy. Swiss Group for Clinical Cancer Research (SAKK).
    Bernhard J; Hürny C; Bacchi M; Joss RA; Cavalli F; Senn HJ; Leyvraz S; Stahel R; Ludwig C; Alberto P
    Br J Cancer; 1996 Nov; 74(10):1660-7. PubMed ID: 8932352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK).
    Joss RA; Alberto P; Hürny C; Bacchi M; Leyvraz S; Thürlimann B; Cerny T; Martinelli G; Stahel R; Ludwig C
    Ann Oncol; 1995 Jan; 6(1):41-8. PubMed ID: 7536028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early versus late alternating chemotherapy in small-cell lung cancer. Swiss Group for Clinical Cancer Research (SAKK).
    Joss RA; Bacchi M; Hürny C; Bernhard J; Cerny T; Martinelli G; Leyvraz S; Senn HJ; Stahel R; Siegenthaler P
    Ann Oncol; 1995 Feb; 6(2):157-66. PubMed ID: 7786823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Fatigue and malaise" as a quality-of-life indicator in small-cell lung cancer patients. The Swiss Group for Clinical Cancer Research (SAKK).
    Hürny C; Bernhard J; Joss R; Schatzmann E; Cavalli F; Brunner K; Alberto P; Senn HJ; Metzger U
    Support Care Cancer; 1993 Nov; 1(6):316-20. PubMed ID: 8156249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility of quality of life assessment in a randomized phase III trial of small cell lung cancer--a lesson from the real world--the Swiss Group for Clinical Cancer Research SAKK.
    Hürny C; Bernhard J; Joss R; Willems Y; Cavalli F; Kiser J; Brunner K; Favre S; Alberto P; Glaus A
    Ann Oncol; 1992 Dec; 3(10):825-31. PubMed ID: 1337466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic value of response to the first cycle of chemotherapy in small cell lung cancer. Results of a multicenter German trial.
    Wolf M; Havemann K; Holle R; Harms V; Drings P; Hans K; Dombrowski H; Victor N
    Eur J Cancer Clin Oncol; 1987 Aug; 23(8):1197-205. PubMed ID: 2443363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). II: Quality of life. Medical Research Council Lung Cancer Working Party.
    Bleehen NM; Girling DJ; Machin D; Stephens RJ
    Br J Cancer; 1993 Dec; 68(6):1157-66. PubMed ID: 7505104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. Medical Research Council Lung Cancer Working Party.
    Br J Cancer; 1996 Feb; 73(3):406-13. PubMed ID: 8562352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ifosfamide, carboplatin, and etoposide with midcycle vincristine versus standard chemotherapy in patients with small-cell lung cancer and good performance status: clinical and quality-of-life results of the British Medical Research Council multicenter randomized LU21 trial.
    Thatcher N; Qian W; Clark PI; Hopwood P; Sambrook RJ; Owens R; Stephens RJ; Girling DJ
    J Clin Oncol; 2005 Nov; 23(33):8371-9. PubMed ID: 16293867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). I: Survival and prognostic factors. Medical Research Council Lung Cancer Working Party.
    Bleehen NM; Girling DJ; Machin D; Stephens RJ
    Br J Cancer; 1993 Dec; 68(6):1150-6. PubMed ID: 8260367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of chemo-radiotherapy and prognostic factors of small cell lung cancer.
    Shikaura S; Kawa S; Yoshida M; Yonezu S
    Radiat Med; 1991; 9(2):70-6. PubMed ID: 1658856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of life as subjective experience: reframing of perception in patients with colon cancer undergoing radical resection with or without adjuvant chemotherapy. Swiss Group for Clinical Cancer Research (SAKK).
    Bernhard J; Hürny C; Maibach R; Herrmann R; Laffer U
    Ann Oncol; 1999 Jul; 10(7):775-82. PubMed ID: 10470423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
    Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
    Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulmonary toxicity with combined modality therapy for limited stage small-cell lung cancer.
    Brooks BJ; Seifter EJ; Walsh TE; Lichter AS; Bunn PA; Zabell A; Johnston-Early A; Edison M; Makuch RW; Cohen MH
    J Clin Oncol; 1986 Feb; 4(2):200-9. PubMed ID: 3003259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health-related quality of life in early breast cancer.
    Groenvold M
    Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage chemotherapy with CCNU and methotrexate for small cell lung cancer resistant to CAV/PE alternating chemotherapy.
    Gridelli C; Contegiacomo A; Lauria R; Gentile M; Airoma G; De Placido S; Perrone F; Ferrante G; Bianco AR
    Tumori; 1991 Dec; 77(6):506-10. PubMed ID: 1666468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Report to the Medical Research Council by its Lung Cancer Working Party.
    Br J Cancer; 1989 Apr; 59(4):584-90. PubMed ID: 2540789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality-of-life assessment in cancer clinical trials: an intervention by itself?
    Bernhard J; Gusset H; Hürny C
    Support Care Cancer; 1995 Jan; 3(1):66-71. PubMed ID: 7697305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison of 2 regimens of chemotherapy of small cell carcinoma of the lung: modified Hansen method and the ACOM method].
    Jassem J; Karnicka-Młodkowska H; Mierzewski P; Decker E; Krawczyk K; Lisowska B; Malak K; Słupek A; Sokół A; Sosnowski K
    Pneumonol Pol; 1988 Apr; 56(4):142-51. PubMed ID: 2842737
    [No Abstract]   [Full Text] [Related]  

  • 20. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.
    Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Hatlevoll R; Dahle R; Boye N; Wang M; Vigander T; Vilsvik J; Skovlund E; Hannisdal E; Aamdal S;
    J Clin Oncol; 2002 Dec; 20(24):4665-72. PubMed ID: 12488411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.